http://www.optionsclearing.com/webapps/infomemos;...occ...
siehe no. 40016
Biodel Inc. (BIOD) has announced a 1-for-30 reverse stock split and a name/symbol/CUSIP change. As a result of the reverse stock split and name/symbol/CUSIP change, each BIOD Common Share will be converted into the right to receive approximately 0.033333 (New) Albireo Pharma, Inc. Common Shares.
(New) Albireo Pharma, Inc. Common Shares will trade on the Nasdaq Stock Market under the trading symbol
“ALBO”. The reverse stock split and name/symbol/CUSIP change will become effective before the market
open on November 4, 2016.
CONTRACT ADJUSTMENT
Effective Date: November 4, 2016
Option Symbol: BIOD changes to ALBO1
Contract
Multiplier: 1
Strike Divisor: 1
New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will equal $100)
New Deliverable
Per Contract: 1) 3 (New) Albireo Pharma, Inc. (ALBO) Common Shares
2) Cash in lieu of approximately 0.3333 fractional ALBO Shares
CUSIP: ALBO (New): 01345P106
PRICING
Until the cash in lieu amount is determined, the underlying price for ALBO1 will be determined as follows:
ALBO1 = 0.033333 (ALBO)
DELAYED SETTLEMENT
The ALBO component of the ALBO1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the ALBO1 deliverable until the cash in lieu of fractional ALBO Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.
DISCLAIMER
This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate allinformation concerning this corporate event(s).
The determination to adjust options and the nature of any adjustment is made by a panel of The OCC
Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC ByLaws,
Article XII, Sections 3, 25, or 25A, as applicable. For both options and futures, each adjustment
decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.
ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES
AND CORRESPONDENTS ON THE ABOVE.
For questions regarding this memo, call Investor Services at 1-888-678-4667 or email
investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or,
within Canada, at 1-800-424-7320, or email memberservices@theocc.com |
